Antimycobacterial activity of an anthracycline produced by an endophyte isolated from Amphipterygium adstringens
The search for new compounds effective against Mycobacterium tuberculosis is still a priority in medicine. The evaluation of microorganisms isolated from non-conventional locations offers an alternative to look for new compounds with antimicrobial activity. Endophytes have been successfully explored as source of bioactive compounds. In the present work we studied the nature and antimycobacterial activity of a compound produced by Streptomyces scabrisporus, an endophyte isolated from the medicinal plant Amphipterygium adstringens. The active compound was detected as the main secondary metabolite present in organic extracts of the streptomycete and identified by NMR spectroscopic data as steffimycin B (StefB). This anthracycline displayed a good activity against M. tuberculosis H37Rv ATCC 27294 strain, with MIC100 and SI values of 7.8 µg/mL and 6.42, respectively. When tested against the rifampin mono resistant M. tuberculosis Mtb-209 pathogen strain, a better activity was observed (MIC100 of 3.9 µg/mL), suggesting a different action mechanism of StefB from that of rifampin. Our results supported the endophyte Streptomyces scabrisporus as a good source of StefB for tuberculosis treatment, as this anthracycline displayed a strong bactericidal effect against M. tuberculosis, one of the oldest and more dangerous human pathogens causing human mortality.
KeywordsAnthracyclines Endophytes Streptomyces scabrisporus Steffimycin B Mycobacterium tuberculosis Amphipterygium adstringens Rifampin Tuberculosis
This work was partially supported by the NUATEI program from Instituto de Investigaciones Biomédicas, and by PAPIIT (IN202216), DGAPA UNAM, México. We are indebted to Beatriz Ruiz-Villafán and Erika Segura Salinas for technical assistance in this work. The help of Marco A. Ortiz-Jiménez for strain preservation studies is recognized. We thank the support of CONACYT Project Number INFR-2017-01 279880, which allowed the acquisition of an HPLC masses.
Compliance with ethical standards
Conflict of interests
The authors declare that they have no conflict of interests.
This article does not contain any studies with human participants performed by any of the authors.
- 3.Kumar V, Patel S, Jain R (2016) New structural classes of antituberculosis agents. Med Res Rev 38(2):1–57Google Scholar
- 12.Gohar YM, El-Naggar MY (2001) Induction of sporulation and antibacterial activity in the aerial mycelium negative mutants of Streptomyces nasri. Egypt J Biol3:23–35Google Scholar
- 15.Linstrom PJ, Mallard WG (2015) NIST Chemistry WebBook, NIST Standard Reference Database. National Institute of Standards and Technology, Gaithersburg; 20899. http://webbook.nist.gov/chemistry/
- 23.Lalitha P, Veena V, Vidhyapriya P, Lakshmi P, Krishna R, Sakthivel N (2016) Anticancer potential of pyrrole (1,2,a) pyrazine 1,4-dione, hexahydro 3-(2-methyl propyl) (PPDHMP) extracted from a new marine bacterium, Staphylococcus sp. strain MB30. Apoptosis 21(5), 566–577Google Scholar
- 24.Ser H-L, Palanisamy UD, Yin W-F, Abd Malek SN, Chan K-G, Goh B-H, Lee L-H (2015) Presence of antioxidative agent, Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro—in newly isolated Streptomyces mangrovisoli sp. nov. Front Microbi 6:854Google Scholar
- 25.Nirjanta D, Wahab F (2012) Antimicrobial properties of endophytic fungi isolated from medicinal plant Camellia sinesis. Int J Pharm Bio Sci. 3:P420–P427Google Scholar
- 29.Gao W, Kim JY, Anderson JR, Akopian T, Hong S, Jin YY, Kandror O, Kim JW, Lee IA, Lee SY, McAlpine JB, Mulugeta S, Sunoqrot S, Wang Y, Yang SH, Yoon TM, Goldberg AL, Pauli GF, Suh JW, Franzblau SG, Cho S (2014) The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo. Antimicrobial Agents Chemother 59(2):880–889CrossRefGoogle Scholar
- 34.Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier VA (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707):223–227CrossRefGoogle Scholar